Online inquiry

IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6906MR)

This product GTTS-WQ6906MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets Alkaline phosphatase substitute gene. The antibody can be applied in Hypophosphatasia (HPP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000478.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 249
UniProt ID P05186
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6906MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7162MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FG-3019
GTTS-WQ10188MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ11601MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MGAH-22
GTTS-WQ7066MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ2522MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ11634MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ3337MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ11423MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-8897
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW